Protagonist Therapeutics vs 10x Genomics

Protagonist Therapeutics (PTGX), health care, and 10x Genomics (TXG), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Protagonist Therapeutics is worth $8.1B on the stock market and 10x Genomics $7.4B: Protagonist Therapeutics is valued at 10% more. Protagonist Therapeutics's operating margin in its latest fiscal year was -344% and 10x Genomics's -9.49%. Over the past year Protagonist Therapeutics's share price has moved +47.9% and 10x Genomics's +253%.

Key facts

Protagonist Therapeutics market value
$8.1B
10x Genomics market value
$7.4B
Protagonist Therapeutics P/E
26.4
Protagonist Therapeutics revenue
$46MFY to 2025-12-31
10x Genomics revenue
$642.8MFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

Protagonist Therapeutics vs 10x Genomics: every measure side by side
Measure Protagonist Therapeutics 10x Genomics
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$8.1Bhigher$7.4Blower
Revenue$46Mlower$642.8Mhigher
Earnings-$130.1Mlower-$43.5Mhigher
Employees149lower1,178higher
Total assets$668.2Mlower$1Bhigher
Valuation
P/E26.4—
P/S177higher11.5lower
P/B7.5lower8.8higher
Dividend yield0.00%0.00%
Profitability
Operating margin-344%lower-9.49%higher
Balance sheet
Net assets$614.7Mlower$796.3Mhigher
Total liabilities$53.5Mlower$245Mhigher
Total debt——
Cash on hand$128.4Mlower$474Mhigher
Price change
Today-0.13%lower+2.38%higher
1 year+47.9%lower+253%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (1)

Protagonist Therapeutics only (2)

10x Genomics only (2)

Percentages are each holding's share of that investor's reported portfolio (under "Both": Protagonist Therapeutics / 10x Genomics). Who owns PTGX · Who owns TXG

Further comparisons

Learn

Questions and answers

Which is bigger, Protagonist Therapeutics or 10x Genomics?

By market value, Protagonist Therapeutics is the larger: $8.1B against $7.4B for 10x Genomics. By revenue in its latest fiscal year, 10x Genomics is the larger: $642.8M against $46M for Protagonist Therapeutics.

Which has the higher operating margin?

10x Genomics: -9.49%, against -344% for Protagonist Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Protagonist Therapeutics and 10x Genomics?

In their latest 13F filings, Stanley Druckenmiller holds both.

Cite this page

Funkfolio, “Protagonist Therapeutics vs 10x Genomics”, data as of 18 November 2026. https://funkfolio.com/compare/ptgx-vs-txg

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.